Vaderis is a clinical stage biotechnology company focussed on the treatment of rare and orphan diseases caused by Vascular Malformations. — vaderis.com
Investors 1
| Date | Name | Website |
| - | Droia Onco... | droiaventu... |
Mentions in press and media 4
| Date | Title | Description |
| 20.11.2024 | FDA approval and a key partnership to accelerate drug development | The Fast Track Designation from the U.S. Food and Drug Administration (FDA) is aimed at accelerating the development and review process for drugs that address unmet medical needs, offering benefits like priority review, increased interacti... |
| 30.08.2024 | US and European approvals open new avenues for Swiss Biotechs | Life Molecular Imaging (LMI), a partner of AC Immune has received Fast Track Designation for the Tau positron emission tomography (PET) diagnostic, [18F]PI-2620, from the U.S. Food and Drug Administration (FDA) in three neurodegenerative c... |
| 27.08.2024 | Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT | Trial delivers positive results in first ever industry-led clinical trial in Hereditary Haemorrhagic Telangiectasia (HHT) VAD044 showed favourable safety and tolerability, together with exploratory efficacy across key manifestations of the ... |
| 22.08.2022 | From stealth mode into clinical trials |